BAD HOMBURG, Germany--(BUSINESS WIRE)--Fresenius Medical Care AG & Co. KGaA, the world’s largest provider of dialysis products and services, today announced that it signed exclusive license agreements for the intravenous (IV) Iron products Venofer® (iron sucrose) and Ferinject® (ferric carboxymaltose) to treat iron deficiency anemia experienced by dialysis patients. Venofer® is the leading IV Iron product worldwide.
The agreement concerns all commercialization activities for these IV Iron products in the field of dialysis and is expected to become effective not later than January 1st, 2009.
As part of the 10-year Agreement for North America....
I think you are missing the point of Rockwell's SFP. SFP is given with the dialysis treatment and provides low levels of iron to the bloodstream over time as opposed to single high doses like Venofere and Ferinject.
Fresenius doesn't have the option to use SFP at this time since it hasn't been through clinical testing yet. Once it is proven out, who would not want to provide iron through dialysis if its CHEAPER to the dialysis provider and is more effective than other IV iron drugs? Effectiveness and cost will drive SFP in the marketplace if it proves out. Venofer may become completely obsolete.
yeap...if Fresenius thought Rockwell had even a distant shot at this than why sign a 10 year exclusive distrib agreement for IV?!?!?! If not Fresenius clinics then who would buy SFP? Davita clinics are frantically switching to Fresenius granulfo..so who is left of any significance to sell? Best of luck.